Bopindolol, pindolol, and atenolol in patients with chronic obstructive lung disease.
Twelve subjects with chronic obstructive lung disease and a partially reversible obstruction received increasing single doses of bopindolol (1, 2, 4, and 8 mg), pindolol (7.5, 15, and 30 mg), and atenolol (50 and 100 mg). Resting heart rate and blood pressure were reduced in a dose-dependent fashion. The actions of the drugs on lung function were assessed by whole body plethysmography. Pindolol did not influence mean airway resistance (Raw). Bopindolol (1, 2 and 4 mg) and atenolol (50 mg) exhibited a neutral effect on mean Raw. Atenolol (100 mg) and to a lesser extent bopindolol (8 mg) induced a long-lasting increase in mean Raw.
Dorow
P
P
Schiess
W
W
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000403:Airway Resistance / Q000187:drug effects; D001262:Atenolol / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010869:Pindolol / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D010993:Plethysmography, Whole Body
D000319:Adrenergic beta-Antagonists; D001262:Atenolol; D010869:Pindolol; C036007:bopindolol